Truist Securities has raised its price target for Corcept Therapeutics, citing strong Korlym sales despite growing competition and the potential of its new drug, relacorilant. The firm believes Corcept could achieve $3 billion in revenue within five years, driven by increased market penetration of relacorilant.
Corcept Therapeutics (CORT) stock surged 6.5% in recent trading, driven by strong demand for its sole marketed drug, Korlym, and anticipation for a new drug application for its lead candidate, relacorilant. The company’s earnings and revenue growth expectations are positive, but analysts recommend monitoring for changes in earnings estimates to assess the stock’s future direction.
A puffy face, often referred to as ‘cortisol face,’ can be a telltale sign of elevated cortisol levels, the stress hormone. While occasional cortisol spikes are normal, consistently high levels can indicate a serious health issue, such as Cushing’s syndrome. High cortisol can lead to weight gain, particularly in the face and abdomen, as well as other symptoms like high blood pressure, acne, and mood swings. Learn about the causes, symptoms, and management of high cortisol levels and how to lower your stress for better health.
